Drug or technology

ABBV-295

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · PHASE 2 TRIAL

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

ClinicalTrials.gov

This is a Phase 2 trial registration with no results posted; it describes planned enrollment and outcome measures only, representing early-stage efficacy and safety evaluation of an investigational agent.

PreliminaryObesity ABBV-295 Overweight

Reported

Planned enrollment360

Primary outcome: body weight chan…Percent Change From Baseline in Body Weight…

Primary outcome: adverse eventsNumber of Participants with Adverse Events…

AUG 14, 2026 · PHASE 1 TRIAL

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

ClinicalTrials.gov

Phase 1 safety and tolerability study in healthy volunteers with no results posted; designed to characterize adverse events and pharmacokinetics of a novel agent, not efficacy or clinical benefit.

PreliminaryPlacebo for ABBV-295 ABBV-295 Abbvie

Reported

Planned enrollment24

Phase1

Primary outcome measureNumber of Participants with Adverse Events…